Pharmaceutical Business review -
Pharmaceutical Business Review. Just another WordPress site.
Read Pharmaceutical-business-review.com news digest here: view the latest Pharmaceutical Business Review articles and content updates right away or get to their most visited pages. Pharmaceutical-business-review.com belongs to a large group of moderately popular websites, with around 30K visitors from all over the world monthly. It seems that Pharmaceutical Business Review content is notably popular in USA, as 63.1% of all users (19K visits per month) come from this country. We haven’t detected security issues or inappropriate content on Pharmaceutical-business-review.com and thus you can safely use it. Pharmaceutical-business-review.com is hosted with Pantheon (United States) and its basic language is English.
- Content verdict: Safe
- Website availability: Live
- Language: English
- Last check:
-
988
Visitors daily -
1 976
Pageviews daily -
5
Google PR -
268 636
Alexa rank
Best pages on Pharmaceutical-business-review.com
-
Pharmaceutical Business review -
Get latest News update on Drug Discovery, Clinical Trials, Pharma Regulations, Production & Sales, Packaging & Supply Chain and Pharma Events - Pharmaceutical Business Review
-
B&C Group - Packaging and Logistics Services - Pharmaceutical Business Review
B&C Group is a Clinical Expert that provides world-class packaging and logistics services through Innovative technology and continuous improvement in
-
Helvoet Pharma - Primary and Secondary Packaging Components - Pharmaceutical Business Review
Founded in 1970, today Helvoet Pharma is a leading manufacturer of rubber closures and aluminium caps for injectable drugs, medical disposable devices
Pharmaceutical-business-review.com news digest
-
3 years
TFF Pharmaceuticals, Felix Biotechnology sign LOI for collaboration, development...
Under this proposed CDLA agreement, Felix Biotechnology would obtain a worldwide license to TFF Pharmaceuticals’ Thin Film Freezing technology to develop and manufacture dry powder formulations of a novel, bacteriophage-based biotherapeutics for inhalation...
-
3 years
Merck to buy biopharmaceutical firm VelosBio for $2.75bn
Based in San Diego, VelosBio is involved in the development of first-in-class cancer therapies targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1).
VLS-101, the company’s investigational antibody-drug conjugate (ADC) targeting ROR1, is currently being assessed in a phase I and a phase 2 clinical study to treat patients with haematologic malignancies and solid tumours.... -
3 years
NanOlogy enrols first patient in phase 2 trial of NanoPac for intratumoral treat...
The single arm trial is evaluating up to 3 monthly injections of the investigational drug in patients scheduled for prostatectomy approximately 90 days after the first injection.
Patients will be followed for safety and tumor response. Immune effects will be evaluated via multiplex immunohistochemistry and flow cytometry.... -
3 years
XNK Therapeutics receives US orphan drug status for NK cell-based immunotherapy ...
Receiving ODD status from the FDA for the treatment of multiple myeloma is a critical next step for the development of XNK’s leading investigational drug candidate. XNK has already received ODD status in the EU.
“Obtaining an ODD by the FDA is a significant milestone for XNK and our goal of taking the present drug candidate to the next level,” said Johan Liwing, CEO of XNK Therapeutics. “This is the starting point for us to expand clinical development into the...
Domain history
Web host: | Pantheon |
Registrar: | Register SPA |
Registrant: | REDACTED FOR PRIVACY (New Statesman Media Group Limited) |
Updated: | April 03, 2024 |
Expires: | April 14, 2025 |
Created: | April 14, 2003 |
Whois record
Visitor gender
Male
Female
Safety scores
Trustworthiness
N/AChild safety
N/A